Citigroup Inc. Grows Stake in VanEck Pharmaceutical ETF $PPH

Citigroup Inc. boosted its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 987.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 718,199 shares of the company’s stock after purchasing an additional 652,175 shares during the quarter. Citigroup Inc. owned about 5.80% of VanEck Pharmaceutical ETF worth $64,896,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Clal Insurance Enterprises Holdings Ltd purchased a new stake in VanEck Pharmaceutical ETF during the 2nd quarter valued at approximately $28,587,000. JPMorgan Chase & Co. boosted its position in shares of VanEck Pharmaceutical ETF by 2,852.2% during the second quarter. JPMorgan Chase & Co. now owns 255,837 shares of the company’s stock worth $22,503,000 after acquiring an additional 247,171 shares during the last quarter. Verity & Verity LLC purchased a new position in VanEck Pharmaceutical ETF during the second quarter valued at $11,551,000. Tower Research Capital LLC TRC increased its holdings in VanEck Pharmaceutical ETF by 346,140.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 34,624 shares of the company’s stock valued at $3,046,000 after acquiring an additional 34,614 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in VanEck Pharmaceutical ETF by 53.3% in the 1st quarter. Royal Bank of Canada now owns 67,596 shares of the company’s stock valued at $6,160,000 after acquiring an additional 23,491 shares during the last quarter.

VanEck Pharmaceutical ETF Stock Up 0.5%

PPH opened at $110.90 on Tuesday. The firm has a 50-day simple moving average of $106.32 and a two-hundred day simple moving average of $97.58. VanEck Pharmaceutical ETF has a 52 week low of $77.67 and a 52 week high of $112.58. The company has a market capitalization of $1.22 billion, a PE ratio of 20.21 and a beta of 0.54.

VanEck Pharmaceutical ETF Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 29th were paid a dividend of $0.3106 per share. The ex-dividend date of this dividend was Monday, December 29th. This represents a $1.24 dividend on an annualized basis and a yield of 1.1%.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.